| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Edwards Lifesciences (NYSE:EW) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 6 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 6 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.4, a high estimate of $107.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 6.69% from the previous average price target of $91.29.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Edwards Lifesciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Roman | Goldman Sachs | Announces | Buy | $107.00 | - |
| Joanne Wuensch | Citigroup | Raises | Buy | $105.00 | $98.00 |
| Pito Chickering | Deutsche Bank | Raises | Buy | $103.00 | $86.00 |
| Matt Miksic | Barclays | Raises | Overweight | $101.00 | $100.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $85.00 | $86.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $99.00 | $94.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $89.00 | $92.00 |
| Rick Wise | Stifel | Raises | Hold | $85.00 | $83.00 |
| Adam Maeder | Piper Sandler | Raises | Neutral | $88.00 | $85.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $101.00 | $95.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $105.00 | $95.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $92.00 | $86.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $98.00 | $90.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $103.00 | $95.00 |
| Suraj Kalia | Oppenheimer | Raises | Outperform | $100.00 | $93.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Edwards Lifesciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Edwards Lifesciences showcased positive performance, achieving a revenue growth rate of 9.5% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Edwards Lifesciences's ROE excels beyond industry benchmarks, reaching 5.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Edwards Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: EW
